Gilead Sciences, Inc. (TSX:GILD)

Market Cap	211.68B
Revenue (ttm)	40.51B
Net Income (ttm)	11.30B
Shares Out	n/a
EPS (ttm)	8.95
PE Ratio	18.74
Forward PE	14.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	681
Average Volume	5,126
Open	25.61
Previous Close	25.72
Day's Range	25.39 - 25.61
52-Week Range	20.08 - 26.29
Beta	n/a
RSI	52.14
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GILD

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD